GLP-1 receptor
Jul 14, 2026
Hengrui Pharma Encounters FDA Regulatory Hurdle for Camrelizumab–Rivoceranib; Kailera Therapeutics Announces Positive Results for HRS-7535/KAI-7535 Across Two Phase 3 Studies; Jemperli Underscores Durable Clinical Complete Responses in dMMR/MSI-H Rectal Cancer; FDA Approves PADCEV-Keytruda Combination for Neoadjuvant and Adjuvant Treatment of Muscle-Invasive Bladder Cancer; Sanofi’s Subcutaneous Sarclisa Escena Gains US Approval
Hengrui Pharma Receives FDA Complete Response Letter for Camrelizumab–Rivoceranib Combination in Advanced Liver Cancer Hengrui Pharma and Elevar Therapeutics have encountered another setback in their efforts to secure U.S. approval for the combination of camrelizumab and rivoceranib, as the FDA has issued a thir...
Read More...
Jul 10, 2026
Top Obesity Drugs by Revenue in 2025: The Biggest Winners in the Weight Loss Market
Summary The obesity treatment market has shifted from a niche category to a major pharma growth engine, with revenues in the leading markets rising from about $16 billion in 2025 to a projected $80 billion by 2034 and potentially more than $100 billion by 2036. Eli Lilly led the category in 2025, driven by M...
Read More...
Jun 15, 2026
The Oral GLP-1 Revolution: How Pill-Based Drugs Are Reshaping the Obesity Treatment Space
Summary The obesity drug landscape is shifting from injectable GLP-1s to oral pill-based treatments, marking a major turning point in pharmacotherapy. Two oral GLP-1s have now received FDA approval: Novo Nordisk's WEGOVY pill (December 2025) and Eli Lilly's FOUNDAYO (April 2026). Several companies, such a...
Read More...
Jun 09, 2026
Roche Expands Pipeline Through Global Bexobrutideg Partnership with Nurix Therapeutics; Incyte to Acquire Vega Therapeutics; Tango Therapeutics Unveils Promising Pancreatic Cancer Data with Vopimetostat–Daraxonrasib Combination; Otsuka Announces Encouraging 12-Month eGFR Outcomes from Phase 3 VISIONARY Study of VOYXACT in IgAN; Innovent Biologics Unveils Phase 3 DREAMS-3 Findings for First Approved GCG/GLP-1 Dual Receptor Agonist
Roche and Nurix Therapeutics Partner to Advance BTK Degrader Bexobrutideg Roche has entered into an exclusive licensing and collaboration agreement with Nurix Therapeutics to jointly develop and commercialize bexobrutideg (NX-5948), Nurix’s investigational Bruton’s Tyrosine Kinase (BTK) degrader. Through this pa...
Read More...
Feb 24, 2026
Gilead Sciences to Acquire Arcellx in Strategic Move to Accelerate Anito-cel Development; Novo Nordisk Faces Setback as CagriSema Underwhelms Against Rival Therapy in Trial; Vanda Pharmaceuticals Secures FDA Approval for BYSANTI; All-oral Calquence + venetoclax Combo Clears in the US for First-line Treatment of CLL; Merck’s ENFLONSIA Demonstrates Strong Protection Against Severe RSV in Young Children Over Consecutive Seasons
Gilead Sciences Announces Acquisition of Arcellx to Advance Long-Term Growth of Anito-cel Gilead Sciences announced a definitive agreement to acquire Arcellx, a clinical-stage biotechnology company, in a strategic move to strengthen its leadership in cell therapy and oncology innovation. The acquisition builds o...
Read More...
Jan 27, 2026
Sanofi Strengthens Amlitelimab’s Position in Atopic Dermatitis; Corcept Announces Statistically Significant Overall Survival Benefit in Phase 3 ROSELLA Study; CORXEL Raises $287M Series D1 for Cardiometabolic Pipeline Expansion; IntraBio’s Levacetylleucine Demonstrates Positive Results in Pivotal Ataxia-Telangiectasia Trial; Otsuka Secures FDA Acceptance and Priority Review for Centanafadine in ADHD
Sanofi’s Amlitelimab Demonstrates Promise in Atopic Dermatitis Following the positive findings from the COAST 1 trial (NCT06130566) reported in September 2025, two additional global Phase 3 studies, SHORE (NCT06224348) and COAST 2 (NCT06181435), have further strengthened the clinical evidence supporting amliteli...
Read More...
Jan 23, 2026
JPM 2026 Recap: Who’s Winning, Who’s Catching Up, and Who’s at Risk?
The 44th Annual J.P. Morgan Healthcare Conference, held January 12-15, 2026, in San Francisco, revealed a pharmaceutical sector at an inflection point. With major blockbusters facing patent expirations, industry leaders such as Eli Lilly, Novo Nordisk, Bristol Myers Squibb, AbbVie, Bayer, Pfizer, Novartis, Roche, M...
Read More...
Dec 23, 2025
Novo Nordisk Seeks FDA Approval for CagriSema; EU Approves Subcutaneous Self-administration of SAPHNELO via Pre-filled Pen for SLE; Cytokinetics Secures FDA Approval of MYQORZO for Adult Patients with Symptomatic Obstructive HCM; Boehringer’s JASCAYD Wins FDA Approval for Adult Pulmonary Fibrosis; BioMarin to Acquire Amicus for $4.8B, Advancing Long-Term Growth in Rare Diseases
Novo Nordisk Submits CagriSema for FDA Review as a Once-weekly GLP-1–amylin Combination Therapy for Weight Management Novo Nordisk has officially filed a New Drug Application (NDA) with the U.S. FDA for CagriSema, a once-weekly subcutaneous injection intended for chronic weight management. CagriSema represents a...
Read More...
Nov 25, 2025
Novartis Secures FDA Approval for ITVISMA; Kelun-Biotech’s Phase III Study Shows Sac-TMT + Keytruda Achieves Primary Endpoint in First-Line PD-L1-Positive NSCLC; Evoke Phase 3 Trials Failed to Show a Statistically Significant Impact on Alzheimer’s Disease Progression; Sangamo Therapeutics Gets FDA Nod for Rolling BLA Submission of ST-920 in Fabry Disease; Bayer’s HYRNUO Receives FDA Accelerated Approval for Previously Treated HER2-mutant NSCLC
Novartis Secures FDA Approval of ITVISMA for Children Two Years and Older, Teens, and Adults with Spinal Muscular Atrophy (SMA) Novartis has announced a significant expansion in the treatment landscape for Spinal Muscular Atrophy (SMA) with the FDA approval of ITVISMA (onasemnogene abeparvovec-brve). This one-ti...
Read More...
Oct 31, 2025
Pharma Rivalry Intensifies: Novo Nordisk Looks to Wrest Metsera from Pfizer
In an unprecedented move that has sent shockwaves through the pharmaceutical industry, Danish drugmaker Novo Nordisk launched an unsolicited ~$9 billion bid to acquire obesity-focused biotech Metsera, directly challenging a deal Pfizer had already secured. The aggressive counteroffer, announced on October 30, 2025,...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
